{
    "name": "bupivacaine/meloxicam",
    "comment": "Rx",
    "other_names": [
        "Zynrelef"
    ],
    "classes": [
        "Local Anesthetics",
        "Parenteral",
        "NSAIDs"
    ],
    "source": "https://reference.medscape.com/drug/zynrelef-bupivacaine-meloxicam-1000319",
    "pregnancy": {
        "common": [
            "Data are unavailable on use of bupivacaine/meloxicam in pregnant females to evaluate drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes; however, data are available on the individual components",
            "Data are unavailable on whether drug is present in human milk, or on the effects on breastfed infants, or on milk production"
        ],
        "specific": [
            {
                "type": "Bupivacaine",
                "description": [
                    "There are no studies conducted with pregnant females ",
                    "  ",
                    "  ",
                    "Embryofetal deaths were observed with SC administration of bupivacaine to rabbits during organogenesis at a dose equivalent to 1.6 times the maximum recommended human dose (MRHD) of 266 mg; SC administration of bupivacaine to rats from implantation through weaning produced decreased pup survival at a dose equivalent to 1.5 times the MRHD",
                    "Advise pregnant females of the potential risks to a fetus"
                ]
            },
            {
                "type": "Meloxicam",
                "description": [
                    "Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive",
                    "  ",
                    "  ",
                    "Avoid use of NSAIDs in pregnant women at about 30 weeks' gestation and later; NSAIDs increase risk of premature closure of fetal ductus arteriosus at approximately this gestational age",
                    "Use of NSAIDs at about 20 weeks' gestation or later in pregnancy may also cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment",
                    "These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation",
                    "Oligohydramnios is often, but not always, reversible with treatment discontinuation; complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation",
                    "In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required",
                    "If NSAID treatment is necessary between about 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible",
                    "Consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours; discontinue drug if oligohydramnios occurs and follow up according to clinical practice",
                    "  ",
                    "  ",
                    "Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization",
                    "Administration of prostaglandin synthesis inhibitors, such as meloxicam, resulted in increased preimplantation and postimplantation loss"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "  ",
                    "  ",
                    "Based on the mechanism of action, prostaglandin-mediated NSAIDs may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women",
                    "Animal studies have shown prostaglandin synthesis inhibitors may disrupt prostaglandin-mediated follicular rupture required for ovulation",
                    "Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation",
                    "Consider withdrawal/avoidance of NSAIDs in women who have difficulties conceiving or who are undergoing infertility investigation",
                    "  ",
                    "  ",
                    "Male rats given meloxicam PO for 35 days had decreased sperm count and motility, and histopathological evidence of testicular degeneration at 0.8 times the MRHD based on BSA comparison"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Meloxicam is present in milk of lactating rats at concentrations higher than those in plasma",
                    "Bupivacaine and meloxicam detected in milk of lactating pigs, but only bupivacaine was detected in plasma of piglets"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are unavailable on whether drug is present in human milk, or on the effects on breastfed infants, or on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Cardiovascular risk",
                    "description": [
                        "Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke, which can be fatal",
                        "Risk may increase with duration of use",
                        "Patients with existing cardiovascular disease or risk factors for such disease may be at greater risk",
                        "The risk of these events following single-dose local application of bupivacaine/meloxicam is uncertain",
                        "Contraindicated in setting of coronary artery bypass graft (CABG) surgery"
                    ]
                },
                {
                    "type": "Gastrointestinal risk",
                    "description": [
                        "NSAIDs increase risk of serious GI adverse events, including bleeding, ulceration, and gastric or intestinal perforation, which can be fatal",
                        "GI adverse events may occur at any time during use and without warning symptoms",
                        "Geriatric patients and those with prior history of peptic ulcer disease and/or GI bleeding are at greater risk "
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity (eg, anaphylactic reactions, serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components",
                "History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs reported",
                "Patients undergoing obstetrical paracervical block anesthesia; use of bupivacaine in this technique has resulted in fetal bradycardia and death",
                "Patients undergoing coronary artery bypass graft (CABG) surgery"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Hepatotoxicity",
                    "description": [
                        "Amide-type local anesthetics (eg, bupivacaine) are metabolized by the liver; use cautiously with hepatic impairment",
                        "Increased ALT/AST ≥3x ULN reported (rarely) with NSAID use; rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure, reported ",
                        "Inform patients of warning signs and symptoms of hepatotoxicity (eg, nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms); if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (eg, eosinophilia, rash), promptly evaluate the patient "
                    ]
                },
                {
                    "type": "Bupivacaine",
                    "description": [
                        "Prevent dose-related toxicity by assuring proper dose and correct technique",
                        "Limit exposure to articular cartilage due to the potential risk of chondrolysis",
                        "Chondrolysis reported with intra-articular infusion of local anesthetics; intra-articular infusions of local anesthetics, following arthroscopic and other surgical procedures is an unapproved use"
                    ]
                },
                {
                    "type": "Meloxicam",
                    "description": [
                        "Anaphylaxis and aspirin-sensitive asthma",
                        "May cause anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma",
                        "A subpopulation of patients with asthma may have aspirin-sensitive asthma including severe, potentially fatal bronchospasm; these patients also may may have intolerance to other NSAIDs",
                        "These patients may also be intolerant to other NSAIDs; when used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for exacerbation of asthma symptoms",
                        "Cardiovascular events",
                        "Cardiovascular thrombotic events reported with NSAID use",
                        "Avoid use post myocardial infarction unless benefits outweigh risk; contraindicated in first 10-14 days following CABG",
                        "Avoid use with severe heart failure unless benefits outweigh risk of worsening heart failure",
                        "Fluid retention and edema observed in some patients taking NSAIDs",
                        "Hypertension",
                        "NSAIDs may impair response to loop and thiazide diuretics; monitor blood pressure",
                        "May lead to new-onset hypertension or exacerbate existing hypertension",
                        "GI bleeding, ulceration, and perforation",
                        "Anemia reported in NSAID-treated patients; this may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis",
                        "Monitor hemoglobin or hematocrit if signs or symptoms of anemia occur",
                        "Renal toxicity and hyperkalemia",
                        "Long-term administration of NSAIDs has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury",
                        "Increases in serum potassium concentration, including hyperkalemia, reported with NSAIDs, even in some patients without renal impairment",
                        "NSAIDs may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation; patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly; these effects are reversible upon discontinuation of the NSAID",
                        "Meloxicam may hasten progression of renal dysfunction in patients with preexisting renal disease; because some meloxicam metabolites are excreted by the kidney, monitor patients for signs of worsening renal function; correct volume status in dehydrated or hypovolemic patients prior to initiating therapy ",
                        "Skin reactions",
                        "NSAIDs can cause serious adverse reactions (eg, exfoliative dermatitis, Stevens-Johnson Syndrome [SJS], toxic epidermal necrolysis [TEN], eosinophilia and systemic symptoms [DRESS] syndrome), which can be fatal",
                        "These serious events may occur without warning; inform patients about signs and symptoms of serious skin reactions",
                        "DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling; other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis; sometimes symptoms of DRESS may resemble an acute viral infection; eosinophilia is often present; disorder is variable in its presentation, other organ systems not noted here may be involved; early manifestations of hypersensitivity, such as fever or lymphadenopathy may be present even though rash is not evident; if such signs or symptoms are present, evaluate the patient immediately and treat as clinically indicated ",
                        "Methemoglobinemia",
                        "Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition; if local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia recommended",
                        "Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood; methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death",
                        "Discontinue any oxidizing agents; depending on severity of signs and symptoms, patients may respond to supportive care, ie, oxygen therapy, hydration; a more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen",
                        "Masking of inflammation and fever",
                        "May reduce utility of diagnostic signs in detecting infection by reducing inflammation and fever",
                        "Fetal toxicity",
                        "NSAIDs may cause premature closure of fetal ductus arteriosus, oligohydramnios, and neonatal renal impairment "
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Other local anesthetics",
                        "If unable to avoid coadministration, monitor for neurologic and cardiovascular adverse effects",
                        "Toxic effects of local anesthetics are additive; avoid additional local anesthetic within 96 hr after bupivacaine/meloxicam administration",
                        "Drug-associated methemoglobinemia",
                        "Avoid coadministration of bupivacaine with other drugs that increase risk of methemoglobinemia",
                        "Examples of such drugs include nitrates/nitrites (eg, nitric oxide, nitroglycerin, nitroprusside, nitrous oxide); other local anesthetic; certain antineoplastic agents (eg, cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase); certain antibiotics (eg, dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides); antimalarials (eg, chloroquine, primaquine); anticonvulsants (eg, phenobarbital, phenytoin, sodium valproate); and other drugs (eg, acetaminophen, metoclopramide, quinine, sulfasalazine)",
                        "Drugs interfering with hemostasis",
                        "Monitor if coadministered",
                        "Coadministration of NSAIDs with anticoagulants (eg, warfarin), antiplatelet agents (eg, aspirin), or drugs that inhibit serotonin (eg, SSRIs, SNRIs) may increases risk of bleeding",
                        "Aspirin",
                        "Monitor for signs and symptoms of GI bleeding",
                        "Coadministration of NSAIDs and aspirin associated with increased incidence of GI adverse effects compared with when an NSAID is used alone",
                        "ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers",
                        "Monitor blood pressure, volume, renal function",
                        "NSAIDs may decrease antihypertensive effect of ACE inhibitors, ARBs, or beta-blockers",
                        "Coadministration of NSAIDs with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure, particularly in patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment",
                        "Effect of NSAIDS on selected drugs",
                        "Monitor serum levels (if applicable) and adverse effects",
                        "Digoxin: Coadministration may increase digoxin serum levels",
                        "Lithium: Coadministration may increase plasma lithium levels",
                        "Methotrexate: Coadministration may increase risk for methotrexate toxicity (eg, neutropenia, thrombocytopenia, renal dysfunction)",
                        "Cyclosporine: Coadministration may increase cyclosporine-associated nephrotoxicity ",
                        "Pemetrexed: Coadministration may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sodium polystyrene sulfonate",
            "description": {
                "common": "meloxicam increases toxicity of sodium polystyrene sulfonate by Other (see comment). Contraindicated. \nComment: Cases of intestinal necrosis (possibly fatal) described with concomitant sorbitol and sodium polystyrene sulfonate; due to sorbitol in meloxicam oral suspension, coadministration is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid oral",
            "description": {
                "common": "aminolevulinic acid oral, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid topical",
            "description": {
                "common": "meloxicam, aminolevulinic acid topical.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "meloxicam and apixaban both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benazepril",
            "description": {
                "common": "meloxicam, benazepril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "bupivacaine, bupivacaine implant.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid additional local anesthetic administration within 96 hr following bupivacaine implantation. If use of additional local anesthetics is unavoidable based on clinical need, monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "captopril",
            "description": {
                "common": "meloxicam, captopril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enalapril",
            "description": {
                "common": "meloxicam, enalapril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosinopril",
            "description": {
                "common": "meloxicam, fosinopril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketorolac",
            "description": {
                "common": "meloxicam, ketorolac.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "meloxicam, ketorolac intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisinopril",
            "description": {
                "common": "meloxicam, lisinopril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methotrexate",
            "description": {
                "common": "meloxicam increases levels of methotrexate by decreasing renal clearance. Avoid or Use Alternate Drug. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance toxicity. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methyl aminolevulinate",
            "description": {
                "common": "meloxicam, methyl aminolevulinate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "moexipril",
            "description": {
                "common": "meloxicam, moexipril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pemetrexed",
            "description": {
                "common": "meloxicam increases levels of pemetrexed by unspecified interaction mechanism. Avoid or Use Alternate Drug. Interrupt dosing in all patients taking NSAIDs with long elimination half-lives for at least 5d before, the day of, and 2d following pemetrexed administration. If coadministration of an NSAID is necessary, closely monitor patients for toxicity, especially myelosuppression, renal toxicity, and GI toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perindopril",
            "description": {
                "common": "meloxicam, perindopril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod, bupivacaine.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinapril",
            "description": {
                "common": "meloxicam, quinapril. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration may result in a significant decrease in renal function. NSAIDs may diminish the antihypertensive effect of ACE inhibitors. The mechanism of these interactions is likely related to the ability of NSAIDs to reduce the synthesis of vasodilating renal prostaglandins."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "acebutolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "aceclofenac and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "acemetacin and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "agrimony",
            "description": {
                "common": "meloxicam and agrimony both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "meloxicam increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfalfa",
            "description": {
                "common": "meloxicam and alfalfa both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "meloxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aliskiren",
            "description": {
                "common": "meloxicam will decrease the level or effect of aliskiren by  Other (see comment). Use Caution/Monitor. In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs with drugs that affect RAAS may increase the risk of renal impairment (including acute renal failure) and cause loss of antihypertensive effect. Monitor renal function periodically."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alteplase",
            "description": {
                "common": "meloxicam and alteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "American ginseng",
            "description": {
                "common": "meloxicam and American ginseng both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiloride",
            "description": {
                "common": "amiloride and meloxicam both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "antithrombin alfa and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "antithrombin III and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "meloxicam increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "argatroban",
            "description": {
                "common": "argatroban and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "meloxicam decreases effects of asenapine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "aspirin rectal and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azficel-T",
            "description": {
                "common": "azficel-T, meloxicam. Other (see comment). Use Caution/Monitor. \nComment: Patients taking anticoagulants may experience increased bruising or bleeding at biopsy and/or injection sites. Concomitant use of anticoagulants is not recommended. Decisions regarding continued use or cessation of anticoagulants should be made by a physician."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azilsartan",
            "description": {
                "common": "meloxicam, azilsartan.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bemiparin",
            "description": {
                "common": "bemiparin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "benazepril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "meloxicam increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine liposome",
            "description": {
                "common": "bupivacaine will increase the level or effect of bupivacaine liposome by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. Bupivacaine HCl, when injected immediately before bupivacaine liposome, may impact the pharmacokinetic and/or physicochemical properties when the mg dose of bupivacaine HCl solution exceeds 50% of the bupivacaine liposome dose"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betrixaban",
            "description": {
                "common": "meloxicam, betrixaban.\nEither increases levels of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bimatoprost",
            "description": {
                "common": "bimatoprost, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "bivalirudin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "budesonide",
            "description": {
                "common": "meloxicam, budesonide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bumetanide",
            "description": {
                "common": "meloxicam increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "candesartan",
            "description": {
                "common": "candesartan and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "bupivacaine, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbenoxolone",
            "description": {
                "common": "meloxicam increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dofetilide",
            "description": {
                "common": "bupivacaine, dofetilide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive cardiac effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "carvedilol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "meloxicam increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "meloxicam increases effects of chlorpropamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "meloxicam increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of meloxicam by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "meloxicam and choline magnesium trisalicylate both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinnamon",
            "description": {
                "common": "meloxicam and cinnamon both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "meloxicam, ciprofloxacin. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Mechanism: unknown. Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "clopidogrel, meloxicam.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Clopidogrel and NSAIDs both inhibit platelet aggregation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cordyceps",
            "description": {
                "common": "meloxicam and cordyceps both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "meloxicam, cortisone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "meloxicam increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "meloxicam, cyclosporine.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "dabigatran and meloxicam both increase  anticoagulation. Use Caution/Monitor. Caution is advised, both drugs have the potential to cause bleeding. Concomitant use may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "dalteparin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox, meloxicam. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase GI bleeding, ulceration and irritation. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "defibrotide",
            "description": {
                "common": "defibrotide increases effects of meloxicam by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Defibrotide may enhance effects of platelet inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "meloxicam, deflazacort.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "meloxicam, dexamethasone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "diclofenac and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "diflunisal and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "meloxicam and digoxin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dobutamine",
            "description": {
                "common": "meloxicam increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dong quai",
            "description": {
                "common": "meloxicam and dong quai both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopexamine",
            "description": {
                "common": "meloxicam increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxazosin",
            "description": {
                "common": "meloxicam decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "drospirenone",
            "description": {
                "common": "drospirenone and meloxicam both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "edoxaban",
            "description": {
                "common": "edoxaban, meloxicam.\nEither increases toxicity of the other by anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding, monitor closely. Promptly evaluate any signs or symptoms of blood loss."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "eltrombopag increases levels of meloxicam by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF, meloxicam.\nEither increases toxicity of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine and tenofovir with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "emtricitabine",
            "description": {
                "common": "emtricitabine, meloxicam.\nEither increases levels of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enalapril",
            "description": {
                "common": "enalapril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "enoxaparin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ephedrine",
            "description": {
                "common": "meloxicam increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine",
            "description": {
                "common": "meloxicam increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine racemic",
            "description": {
                "common": "meloxicam increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epoprostenol",
            "description": {
                "common": "meloxicam and epoprostenol both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eprosartan",
            "description": {
                "common": "eprosartan and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "meloxicam increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "etodolac and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fennel",
            "description": {
                "common": "meloxicam and fennel both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "fenoprofen and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "feverfew",
            "description": {
                "common": "meloxicam and feverfew both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil triglycerides",
            "description": {
                "common": "fish oil triglycerides will increase the level or effect of meloxicam by  anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "meloxicam, fludrocortisone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "flurbiprofen and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding; SSRIs inhib. srotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "fondaparinux and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "formoterol",
            "description": {
                "common": "meloxicam increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "forskolin",
            "description": {
                "common": "meloxicam and forskolin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosinopril",
            "description": {
                "common": "fosinopril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "furosemide",
            "description": {
                "common": "meloxicam increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "garlic",
            "description": {
                "common": "meloxicam and garlic both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "gemifloxacin, meloxicam. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "meloxicam increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ginger",
            "description": {
                "common": "meloxicam and ginger both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ginkgo biloba",
            "description": {
                "common": "meloxicam and ginkgo biloba both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "meloxicam increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "meloxicam increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "meloxicam increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "green tea",
            "description": {
                "common": "green tea, meloxicam. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "heparin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "horse chestnut seed",
            "description": {
                "common": "meloxicam and horse chestnut seed both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydralazine",
            "description": {
                "common": "meloxicam decreases effects of hydralazine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "meloxicam increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "meloxicam, hydrocortisone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib will increase the level or effect of meloxicam by  anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "ibuprofen and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "ibuprofen IV and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "meloxicam increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "indomethacin and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irbesartan",
            "description": {
                "common": "irbesartan and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "meloxicam increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "ketoprofen and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "ketorolac and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "ketorolac intranasal and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "labetalol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "latanoprost",
            "description": {
                "common": "latanoprost, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "latanoprostene bunod ophthalmic",
            "description": {
                "common": "latanoprostene bunod ophthalmic, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levalbuterol",
            "description": {
                "common": "meloxicam increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "levofloxacin, meloxicam. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Risk of CNS stimulation/seizure.  Mechanism: Displacement of GABA from receptors in brain."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "levomilnacipran, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. SNRIs may further impair platelet activity in patients taking antiplatelet or anticoagulant drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisinopril",
            "description": {
                "common": "lisinopril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "meloxicam increases levels of lithium by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "lornoxicam and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "losartan and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "meclofenamate and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "mefenamic acid and meloxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mesalamine",
            "description": {
                "common": "mesalamine, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaproterenol",
            "description": {
                "common": "meloxicam increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "meloxicam increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "meloxicam, methylprednisolone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "meloxicam increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mistletoe",
            "description": {
                "common": "meloxicam increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moexipril",
            "description": {
                "common": "moexipril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "moxifloxacin, meloxicam. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxisylyte",
            "description": {
                "common": "meloxicam decreases effects of moxisylyte by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "meloxicam will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "meloxicam and nabumetone both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol, bupivacaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Use extreme caution during concomitant use of bupivacaine and antihypertensive agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "meloxicam and naproxen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of bupivacaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nettle",
            "description": {
                "common": "meloxicam increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of meloxicam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "meloxicam increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olmesartan",
            "description": {
                "common": "olmesartan and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "meloxicam and oxaprozin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "panax ginseng",
            "description": {
                "common": "meloxicam and panax ginseng both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "meloxicam and parecoxib both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pau d'arco",
            "description": {
                "common": "meloxicam and pau d'arco both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegaspargase",
            "description": {
                "common": "pegaspargase increases effects of meloxicam by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perindopril",
            "description": {
                "common": "perindopril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenindione",
            "description": {
                "common": "phenindione and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenoxybenzamine",
            "description": {
                "common": "meloxicam decreases effects of phenoxybenzamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentolamine",
            "description": {
                "common": "meloxicam decreases effects of phentolamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phytoestrogens",
            "description": {
                "common": "meloxicam and phytoestrogens both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol, bupivacaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Use extreme caution during concomitant use of bupivacaine and antihypertensive agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pirbuterol",
            "description": {
                "common": "meloxicam increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol, bupivacaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Use extreme caution during concomitant use of bupivacaine and antihypertensive agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "meloxicam and piroxicam both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pivmecillinam",
            "description": {
                "common": "pivmecillinam, meloxicam.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium acid phosphate",
            "description": {
                "common": "meloxicam and potassium acid phosphate both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium chloride",
            "description": {
                "common": "meloxicam and potassium chloride both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium citrate",
            "description": {
                "common": "meloxicam and potassium citrate both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium iodide",
            "description": {
                "common": "potassium iodide and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pralatrexate",
            "description": {
                "common": "meloxicam increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prasugrel",
            "description": {
                "common": "meloxicam, prasugrel.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Chronic use of NSAIDs with prasugrel may increase bleeding risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "meloxicam decreases effects of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "meloxicam, prednisolone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "meloxicam, prednisone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "meloxicam will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protamine",
            "description": {
                "common": "protamine and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinapril",
            "description": {
                "common": "quinapril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramipril",
            "description": {
                "common": "ramipril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reishi",
            "description": {
                "common": "meloxicam and reishi both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reteplase",
            "description": {
                "common": "meloxicam and reteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "rivaroxaban, meloxicam. Other (see comment). Use Caution/Monitor. \nComment: NSAIDs are known to increase bleeding. Bleeding risk may be increased when NSAIDs are used concomitantly with rivaroxaban. Monitor for signs/symptoms of blood loss."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivastigmine",
            "description": {
                "common": "rivastigmine increases toxicity of meloxicam by pharmacodynamic synergism. Use Caution/Monitor. Monitor patients for symptoms of active or occult gastrointestinal bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "sacubitril/valsartan and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "meloxicam and salicylates (non-asa) both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salmeterol",
            "description": {
                "common": "meloxicam increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "meloxicam and salsalate both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saw palmetto",
            "description": {
                "common": "saw palmetto increases toxicity of meloxicam by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Siberian ginseng",
            "description": {
                "common": "meloxicam and Siberian ginseng both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "silodosin",
            "description": {
                "common": "meloxicam decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "meloxicam, sodium picosulfate/magnesium oxide/anhydrous citric acid.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May be associated with fluid and electrolyte imbalances."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of meloxicam by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of meloxicam by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol",
            "description": {
                "common": "meloxicam, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. \nComment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sparsentan",
            "description": {
                "common": "meloxicam and sparsentan both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Coadministration of NSAIDS, including selective COX-2 inhibitors, may result in deterioration of kidney function (eg, possible kidney failure). Monitor for signs of worsening renal function with concomitant use with NSAIDs. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "spironolactone",
            "description": {
                "common": "spironolactone and meloxicam both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "meloxicam and succinylcholine both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "meloxicam and sulfasalazine both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "meloxicam and sulindac both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tafluprost",
            "description": {
                "common": "tafluprost, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "telmisartan and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temocillin",
            "description": {
                "common": "temocillin, meloxicam.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "meloxicam and tenecteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "tenofovir DF, meloxicam.\nEither increases levels of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of  tenofovir DF with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terazosin",
            "description": {
                "common": "meloxicam decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbutaline",
            "description": {
                "common": "meloxicam increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "ticagrelor, meloxicam.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Increased risk of bleeding with use of ticagrelor and  chronic NSAID use. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticarcillin",
            "description": {
                "common": "ticarcillin, meloxicam.\nEither increases levels of the other by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "meloxicam decreases effects of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "meloxicam increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "meloxicam increases effects of tolbutamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "meloxicam and tolfenamic acid both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "meloxicam and tolmetin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "meloxicam and tolvaptan both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "meloxicam increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trandolapril",
            "description": {
                "common": "trandolapril, meloxicam.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "travoprost ophthalmic",
            "description": {
                "common": "travoprost ophthalmic, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "meloxicam, triamcinolone acetonide injectable suspension.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Concomitant use of NSAIDS and corticosteroids increases the risk of gastrointestinal side effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamterene",
            "description": {
                "common": "triamterene and meloxicam both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "valsartan and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "venlafaxine, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vitamin K1 (phytonadione)",
            "description": {
                "common": "meloxicam increases and vitamin K1 (phytonadione) decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, meloxicam.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "meloxicam, vorapaxar.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "meloxicam, vortioxetine.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "meloxicam, warfarin.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Drugs with antiplatelet properties may increase anticoagulation effect of warfarin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "meloxicam, zanubrutinib.\nEither increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zotepine",
            "description": {
                "common": "meloxicam decreases effects of zotepine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "aceclofenac will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acemetacin",
            "description": {
                "common": "acemetacin will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acyclovir",
            "description": {
                "common": "meloxicam will increase the level or effect of acyclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alendronate",
            "description": {
                "common": "meloxicam, alendronate.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amikacin",
            "description": {
                "common": "meloxicam increases levels of amikacin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aminohippurate sodium",
            "description": {
                "common": "meloxicam will increase the level or effect of aminohippurate sodium by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anamu",
            "description": {
                "common": "meloxicam and anamu both increase  anticoagulation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "aspirin rectal will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "balsalazide",
            "description": {
                "common": "meloxicam will increase the level or effect of balsalazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "bendroflumethiazide will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefadroxil",
            "description": {
                "common": "cefadroxil will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefamandole",
            "description": {
                "common": "cefamandole will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefixime",
            "description": {
                "common": "cefixime will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefpirome",
            "description": {
                "common": "cefpirome will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ceftibuten",
            "description": {
                "common": "ceftibuten will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cephalexin",
            "description": {
                "common": "cephalexin will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "meloxicam will increase the level or effect of chlorpropamide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "meloxicam will increase the level or effect of choline magnesium trisalicylate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol decreases levels of meloxicam by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "creatine",
            "description": {
                "common": "creatine, meloxicam. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction) Combination may have additive nephrotoxic effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "danshen",
            "description": {
                "common": "meloxicam and danshen both increase  anticoagulation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "devil's claw",
            "description": {
                "common": "meloxicam and devil's claw both increase  anticoagulation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diclofenac",
            "description": {
                "common": "diclofenac will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diclofenac topical",
            "description": {
                "common": "diclofenac topical, meloxicam.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Although low, there is systemic exposure to diclofenac topical; theoretically, concomitant administration with systemic NSAIDS or aspirin may result in increased NSAID adverse effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diflunisal",
            "description": {
                "common": "diflunisal will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "disulfiram",
            "description": {
                "common": "disulfiram will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eplerenone",
            "description": {
                "common": "meloxicam decreases effects of eplerenone by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etodolac",
            "description": {
                "common": "etodolac will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felbamate",
            "description": {
                "common": "felbamate will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "fenoprofen will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "feverfew",
            "description": {
                "common": "meloxicam decreases effects of feverfew by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "flurbiprofen will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "meloxicam decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "meloxicam will increase the level or effect of ganciclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gentamicin",
            "description": {
                "common": "meloxicam increases levels of gentamicin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hyaluronidase",
            "description": {
                "common": "hyaluronidase, bupivacaine. Other (see comment). Minor/Significance Unknown. \nComment: Hyaluronidase hastens the onset of local analgesia and reduces swelling, but increases systemic absorption of anesthetic. This decreases the duration of action and increases incidence of systemic reaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Dizziness",
            "percent": "22"
        },
        {
            "name": "Incision site edema",
            "percent": "17"
        },
        {
            "name": "Headache",
            "percent": "14"
        },
        {
            "name": "Incision site erythema",
            "percent": "13"
        },
        {
            "name": "Herniorrhaphy H",
            "percent": "4"
        },
        {
            "name": "Headache",
            "percent": "13"
        },
        {
            "name": "Nausea",
            "percent": "50"
        },
        {
            "name": "Vomiting",
            "percent": "26"
        },
        {
            "name": "Constipation",
            "percent": "24"
        },
        {
            "name": "Hypertension",
            "percent": "19"
        },
        {
            "name": "Pyrexia",
            "percent": "14"
        },
        {
            "name": "Bradycardia",
            "percent": "8"
        },
        {
            "name": "Impaired healing",
            "percent": "6"
        },
        {
            "name": "Muscle twitching",
            "percent": "6"
        },
        {
            "name": "Incision site cellulitis",
            "percent": "4"
        },
        {
            "name": "Wound dehiscence",
            "percent": "4"
        },
        {
            "name": "Incision site infection",
            "percent": "3"
        },
        {
            "name": "Bradycardia",
            "percent": "9"
        },
        {
            "name": "Dysgeusia",
            "percent": "9"
        },
        {
            "name": "Skin odor abnormal",
            "percent": "8"
        },
        {
            "name": "Leukocytosis",
            "percent": "7"
        },
        {
            "name": "Pruritus",
            "percent": "7"
        },
        {
            "name": "Headache",
            "percent": "7"
        },
        {
            "name": "Headache",
            "percent": "7"
        },
        {
            "name": "Anemia",
            "percent": "5"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "5"
        },
        {
            "name": "Hypotension",
            "percent": "5"
        }
    ]
}